XBI250103C60000
- 0.00
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
The S&P 500's 10 Worst Performing Stocks in 2023 Fell Again in 2024
Natera Analyst Ratings
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
17 Analysts Assess Biogen: What You Need To Know
Biogen Analyst Ratings
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
How Is The Market Feeling About United Therapeutics?
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
Peering Into Moderna's Recent Short Interest
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Global enterprises are "fully powered" to borrow money! The scale will reach 8 trillion dollars in 2024, setting a record.
Bankers stated that low financing costs were the initial reason for companies to choose to issue Bonds early, as they wanted to avoid the market volatility risks that could arise around the USA elections. However, after Trump's election victory, the market's credit spreads further narrowed, prompting some companies to decide to lock in their borrowing needs for the following year in order to secure funds under favorable market conditions.
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Looking Into AbbVie's Recent Short Interest
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today